

## DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. Policies are not a supplementation or recommendation for treatment; Providers are solely responsible for the diagnosis, treatment and clinical recommendations for the Member. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (e.g., will be paid for by Molina) for a particular Member. The Member's benefit plan determines coverage – each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their Providers will need to consult the Member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a Member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid Members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP and provide the directive for all Medicare members. References included were accurate at the time of policy approval and publication.

## OVERVIEW

Chronic myelogenous leukemia, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis are myeloproliferative disorders characterized by clonal expansion of abnormal hematopoietic stem/progenitor cells. Myeloproliferative neoplasms (MPNs) are characterized by the dysregulated proliferation of myeloid cells including megakaryocytes and myeloid and erythroid progenitors in the bone marrow resulting in ineffective erythropoiesis, the production of cytokines within the marrow microenvironment, and the reactive deposition of fibrous connective tissue (reticulin or collagen) in the bone marrow, often with osteosclerosis. In later fibrotic stages, the peripheral blood demonstrates teardrop-shaped red cells (e.g., dacrocytes), nucleated red blood cells, and early myeloid forms (e.g., a triad termed leukoerythroblastosis), and extramedullary hematopoiesis results in hepatomegaly and splenomegaly. Most patients with primary myelofibrosis (PMF) present with anemia, marked splenomegaly, early satiety, and hypercatabolic symptoms including severe fatigue, low-grade fever, night sweats, bone pain, and weight loss. (Chao, 2022; Holmberg et al., 2022; Negrin, 2022; Tefferi, 2022; DynaMed, n.d.).

During the clinical course, massive splenomegaly, some hepatomegaly, along with progressive anemia requiring frequent red blood cell transfusions is frequently seen. Portal hypertension might accompany marked splenomegaly and could contribute to variceal bleeding or ascites. The median age for diagnosis is 64-67 years of age and approximately 50-65% of patients are positive for the Janus2 kinase (JAK2 V617F) mutation and 26-35% with mutations in CALR (calreticulin). At the current time, allogeneic hematopoietic cell transplantation (HCT) constitutes the only treatment modality with a curative potential in PMF. Other treatment modalities are only palliative and include ruxolitinib as first-line therapy for management of disease-related symptoms. Hydroxyurea considered first-line therapy for control of hyperproliferation manifestations of myelofibrosis (constitutional symptoms, hepatosplenomegaly, and reduction of leukocytosis and thrombocytosis). (Chao, 2022; Holmberg et al., 2022; Negrin, 2022; Tefferi, 2022; DynaMed, n.d.).

Management of patients with PMF is determined by the risk of disease progression and estimated overall survival as calculated by prognostic scores. The International Prognostic Scoring System (IPSS), the Dynamic International Prognostic Scoring System (DIPSS) and the Dynamic International Prognostic Scoring System Plus (DIPSS-Plus) score are the three most common scores used for risk stratification. IPSS should be used at time of diagnosis and DIPSS-Plus incorporates karyotyping and is used during the course of treatment. DIPSS can be used if karyotyping is not available. The DIPSS and DIPSS-Plus scoring systems are outlined below.

The score assigns points for the following five variables:

- Age >65 years: 1 point
- Leukocyte count >25,000/microL (>25 x 10<sup>9</sup>/L): 1 point
- Hemoglobin <10 g/dL (<100 g/L): 2 points
- Circulating blast cells ≥1%: 1 point
- Constitutional symptoms\*: 1 point

# Molina Clinical Policy

## Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis / Myeloproliferative Neoplasms: Policy No. 324

Last Approval: 10/12/2022

Next Review Due By: October 2023



The resulting score is interpreted as follows:

- 0 points – low risk
- 1 to 2 points – intermediate-1 risk
- 3 to 4 points – intermediate-2 risk
- 5 to 6 points – high risk

The DIPSS-Plus score assigns points for the following variables:

- DIPSS low risk: 0 points
- DIPSS intermediate-1 risk: 1 point
- DIPSS intermediate-2 risk: 2 points
- DIPSS high risk: 3 points
- Unfavorable karyotype\*\*: 1 point
- Platelet count <100,000/microL (<100 x 10<sup>9</sup>/L): 1 point
- Anemia requiring transfusion: 1 point

The resulting score is interpreted as follows:

- 0 points – low risk
- 1 point – intermediate-1 risk
- 2 to 3 points – intermediate-2 risk
- 4 to 6 points – high risk

\* Constitutional symptoms include weight loss >10% of the baseline value in the year preceding PMF diagnosis, and/or unexplained fever or excessive sweats persisting for more than one month.

\*\* Unfavorable karyotype includes complex karyotype or one or two abnormalities that include +8, -7/7q-, i(17q), -5/5q-, 12p-, inv(3), 11q23.

### Stem Cell Transplantation

Stem-cell transplantation refers to transplantation of hematopoietic stem cells (HSCs) from a donor into a patient. HSCs are immature cells that can develop into any of the three types of blood cells (red cells, white cells or platelets). HSCs are created in the bone marrow and are found in the bone marrow and peripheral blood. There is also a high concentration of HSCs in umbilical-cord blood. Hematopoietic stem cell transplantation (HSCT) can be either autologous (using the person's own stem cells) or allogeneic (using stem cells from a donor). In allogeneic HSCT, it is preferable for donors to have a human leukocyte antigen (HLA) type that is identical to the recipient. Matching is performed on the basis of variability at three or more loci of the HLA gene (e.g., HLA-A, HLA-B, HLA-DRB1). As HLA variability increases, transplant-related morbidity and mortality, including graft rejection and graft-versus-host disease, also increase. (Chao, 2022; Holmberg et al., 2022; Negrin, 2022; Tefferi, 2022; DynaMed, n.d.).

### Pretransplant Evaluation

The goal of the pretransplant evaluation is to assess the ability of a patient to tolerate the surgery, post-operative immunosuppression, and transplant care. An extensive cardiopulmonary evaluation, screening for occult infection or cancer, and psychosocial evaluation is standard. Specific testing varies depending upon the patient's age, medical history, and transplant center practice. In addition, while a certain battery of tests may initiate the work up, more testing may be indicated depending upon the condition of the patient or the initial test results. In addition to a standard medical evaluation the initial assessment should include a psychological and social support evaluation to identify issues that may impair a successful outcome after transplantation. These include a lack of information about the nature of the transplant procedure and post-transplant care, drug or alcohol dependence, compliance with complex medical and behavior regimens. The assessment includes education of the family and the support network of the patient because compliance with complex medical and behavior treatment is critical after any organ transplant procedure. Recipients must be able to incorporate complicated medications, follow-up appointments, and frequent laboratory visits into their schedules. Having an adequate support network aware of these requirements will encourage patient compliance and long-term success. (Chao, 2022; Holmberg et al., 2022; Negrin, 2022; Tefferi, 2022; DynaMed, n.d.).

## COVERAGE POLICY

All transplants require prior authorization from the Corporate Transplant Department. Solid organ transplant requests will be reviewed by the Corporate Senior Medical Director or qualified clinical designee. All other transplants will be reviewed by the Corporate Senior Medical Director or covering Medical Director. If the criteria are met using appropriate NCD and/or LCD guidelines, State regulations, and/or MCP policies the Corporate Senior Medical Director's designee can approve the requested transplant.

*Office visits with participating Providers do NOT require prior authorization. Providers should see the Member in office visits as soon as possible and without delay. Failure to see the Member in office visits may be considered a serious quality of care concern.*

### **Pre-Transplant Evaluation**

(Chao, 2022; Holmberg et al., 2022; NCCN, 2022; NCI, 2022; Negrin, 2022; Tefferi, 2022; AMR, 2018; CMS, 2016; Majhail et al., 2015; Tefferi & Vardiman, 2008; DynaMed, n.d.; ECOG, n.d.; <sup>1-5</sup> NMDP, n.d.)

**Please see MCP-323 Pre-Transplant Evaluation for additional criteria and information.**

Criteria for transplant evaluation include:

1. History and physical examination; **AND**
2. Psychosocial evaluation and clearance:
  - a. No behavioral health disorder by history or psychosocial issues:
    - If history of behavioral health disorder, no severe psychosis or personality disorder;
    - Mood/anxiety disorder must be excluded or treated;
    - Member has understanding of surgical risk and post procedure compliance and follow-up required.

**AND**

- b. Adequate family and social support.

**AND**

3. EKG; **AND**
4. Chest x-ray; **AND**
5. Cardiac clearance in the presence of any of the following:
  - a. Chronic smokers; **OR**
  - b. Members > 50 years age; **OR**
  - c. Those with a clinical or family history of heart disease or diabetes.

**AND**

6. Pulmonary clearance if evidence of pulmonary artery hypertension (PAH) or chronic pulmonary disease; **AND**
7. Neurological exam and clearance for transplant including **ONE** of the following:
  - a. Normal exam by H&P; **OR**
  - b. Abnormal neurological exam with positive findings including **ONE** of the following:
    - Lumbar puncture normal cytology; **OR**
    - Lumbar puncture with cytological exam abnormal: CNS disease treated prior to clearance.

**AND**

8. A Performance Status that includes **ONE** of the following:
  - a. Karnofsky score 70-100%; **OR**
  - b. Eastern Cooperative Oncology Group (ECOG) Grade 0-2.

**Molina Clinical Policy**  
**Hematopoietic Stem Cell Transplantation for Primary**  
**Myelofibrosis / Myeloproliferative Neoplasms: Policy No. 324**

Last Approval: 10/12/2022

Next Review Due By: October 2023



**AND**

9. Lab studies that include:

- a. Complete blood count; kidney profile (blood urea nitrogen, creatinine); electrolytes; calcium; phosphorous; albumin; liver function tests; and coagulation profile (prothrombin time, and partial thromboplastin time);\*
- b. Serologic screening for: HIV; Epstein Barr virus (EBV); Hepatitis virus B (HBV); Hepatitis C (HCV); cytomegalovirus (CMV); RPR and/or FTA:\*

  - If HIV positive **ALL** of the following must be met:
    - i. CD4 count >200 cells/mm-3 for >6 months; **AND**
    - ii. HIV-1 RNA undetectable; **AND**
    - iii. On stable anti-retroviral therapy >3 months; **AND**
    - iv. No other complications from AIDS (e.g., opportunistic infection, including aspergillus, tuberculosis, coccidioides mycosis, resistant fungal infections, Kaposi's sarcoma, or other neoplasm).
  - If abnormal serology, need physician plan to address and/or treatment as indicated.
    - i. Antinuclear antibody, smooth muscle antibody, antimitochondrial antibody
    - ii. Ceruloplasmin,  $\alpha$ 1-antitrypsin phenotype
    - iii. Alpha-fetoprotein

- c. Urine drug screen (UDS) if Member is current or gives a history of past drug abuse.

**AND**

10. Colonoscopy (if indicated or if Member is age  $\geq$  50) with complete workup and treatment of abnormal results as indicated; an initial screening colonoscopy after initial negative screening requires a follow-up colonoscopy every 10 years).\*

**AND**

11. Gynecological examination with Pap smear for women ages  $\geq$  21 to  $\leq$  65 years of age or if indicated (not indicated in women who have had a total abdominal hysterectomy [TAH] or a total vaginal hysterectomy [TVH]) within the last three years with complete workup and treatment of abnormal results as indicated.

Within the last 12 months:

1. Dental examination or oral exam showing good dentition and oral care or no abnormality on panorex or plan for treatment of problems pre- or post-transplant; **AND**
2. Mammogram (if indicated or > age 40) with complete workup and treatment of abnormal results as indicated;\*
3. PSA if history of prostate cancer or previously elevated PSA with complete workup and treatment of abnormal results as indicated.\*

\* Participating Centers of Excellence may waive these criteria.

**Criteria for Hematopoietic Allogeneic Stem Cell Transplantation (HSCT)**

(Chao, 2022; Holmberg et al., 2022; Negrin, 2022; Tefferi, 2022; Kröger et al., 2015; DynaMed, n.d.)

Hematopoietic Allogeneic Stem Cell Transplantation (HSCT) ablative or non-myeloablative from a human leukocyte antigen (HLA)-matched donor (e.g., at least six out of eight match of the HLA-A, HLA-B, HLA-C and HLA-DRB1 markers) or from cord blood when there are no matched sibling or unrelated donors (e.g., at least four out of six match of the HLA-A, HLA-B and HLA-DRB-1 markers) **may be authorized in adults and children** for the treatment of Primary Myelofibrosis (Myeloproliferative Neoplasms MPS) when **ALL** of the following criteria are met:

1. All pre-transplant criteria are met; **AND**
2. For age < 45 years, conventional intensity conditioning (CIC) allo-HSCT is recommended; **OR**
3. For age > 45 years, reduced intensity conditioning allo-HSCT is recommended; **AND**

**Molina Clinical Policy**  
**Hematopoietic Stem Cell Transplantation for Primary**  
**Myelofibrosis / Myeloproliferative Neoplasms: Policy No. 324**

Last Approval: 10/12/2022

Next Review Due By: October 2023



4. Any of the following clinical indications (see table above for additional scoring information):

a. High risk disease defined as the following:

- DIPSS-Plus score of 4-6 points; **OR**
- DIPSS score of 5-6 points.

**OR**

b. Intermediate risk disease defined as the following:

- DIPSS-Plus score of 1 point for intermediate-1 risk (INT-1); **OR**
- DIPSS-Plus score of 2-3 points for intermediate-2-risk (INT-2); **OR**
- DIPSS score of 1-2 points for intermediate-1 risk (INT-1), **OR**
- DIPSS score of 3-4 points for intermediate-2-risk (INT-2).

**OR**

c. Any PMF-MPS disease with poor prognostic features including any of the following:

- Dependent on transfusions of red blood cells; **OR**
- Dependent on transfusions of platelets or has frequent infarctions; **OR**
- Has an absolute neutrophil count less than 1000/mm<sup>3</sup>; **OR**
- Resistant to conservative therapy with poor initial response or at progression of disease.

**AND**

5. The requesting transplant recipient should not have any of the following absolute contraindications:

- Cardiac, pulmonary, and nervous system disease that cannot be corrected and is a prohibitive risk for surgery; **OR**
- Malignant neoplasm with a high risk for reoccurrence, non-curable malignancy (excluding localized skin cancer); **OR**
- Systemic and/or uncontrolled infection; **OR**
- AIDS (CD4 count < 200cells/mm<sup>3</sup>); **OR**
- Unwilling or unable to follow post-transplant regimen:
  - Documented history of non-compliance
  - Inability to follow through with medication adherence or office follow-up

**OR**

- Chronic illness with one year or less life expectancy; **OR**
- Limited, irreversible rehabilitation potential; **OR**
- Active untreated substance abuse issues, requires documentation supporting free from addiction for minimally 6 months if previous addiction was present; **OR**
- No adequate social/family support.

**AND**

6. The requesting transplant recipient should be evaluated carefully and potentially treated if any of the relative contraindications below are present. (Irreversible lung disease patients require consultation and clearance by a Pulmonologist prior to consideration of transplantation).

- Smoking, documentation supporting free from smoking for 6 months; **OR**
- Active peptic ulcer disease; **OR**
- Active gastroesophageal reflux disease; **OR**
- CVA with long term impairment that is not amendable to rehabilitation or a patient with CVA/transient ischemic attack within past 6 months; **OR**
- Obesity with body mass index of >30 kg/m<sup>2</sup> may increase surgical risk; **OR**
- Chronic liver disease such as Hepatitis B/C/D, or cirrhosis which increases the risk of death from sepsis and hepatic failure requires consultation by a gastroenterologist or hepatologist; **OR**
- Gall bladder disease requires ultrasound of the gall bladder with treatment prior to transplantation.

**Molina Clinical Policy**  
**Hematopoietic Stem Cell Transplantation for Primary**  
**Myelofibrosis / Myeloproliferative Neoplasms: Policy No. 324**

Last Approval: 10/12/2022

Next Review Due By: October 2023



**Criteria for Subsequent Hematopoietic Allogeneic Stem Cell Transplantation (HSCT)**

Hematopoietic Allogeneic Stem Cell Transplantation (HSCT) (ablative or non-myeloablative) **may be authorized after the first prior stem cell transplantation has occurred only one time** for members with MDS who meet all of the above criteria for transplant and have **ANY** of the following:

1. Primary graft failure indicated by no signs of engraftment\* by 42 days after the transplant; **OR**
2. Failure to engraft\*; **AND**
3. Late relapse (greater than 18 months after HCT) as salvage therapy.

\*NOTE: Engraftment is defined as the first 3 consecutive days on which the absolute neutrophil count (ANC) exceeds  $5 \times 10^9/L$  or  $> ANC500$  at any time after transplantation (<sup>2</sup> NMDP, n.d.).

**For Members with Significant or Daily Marijuana Use**

1. Documentation of compliance with a physician prescribed and managed program of abstinence, and a reasonable expectation that the Member will be abstinent from marijuana use during the transplant and immediate post-transplant time period. Daily marijuana use is an absolute contraindication for both transplant and pre-transplant evaluation unless there is a state mandate applicable for medical marijuana use and transplants, and there is documentation of Member compliance with a physician prescribed plan of care for prescribed marijuana use.
2. If the Member's marijuana use is in compliance with a formal, State-based program for managed medical marijuana, the request should include:
  - Documentation of the Plan of Care for medical marijuana (including the medical decision making that supports the use of medical marijuana); **AND**
  - Transplant Provider agreement with the Plan of Care (including agreement to be accountable for managing the Member's use of medical marijuana).

**Continuation of Therapy**

When extension of a previously approved transplant authorization is requested, review using updated clinical information is appropriate.

1. If Molina Healthcare has authorized prior requests for transplantation **ALL** of the following information is required for medical review:
  - a. Presence of no absolute contraindication as listed above; **AND**
  - b. History and physical within the last 12 months; **AND**
  - c. Kidney profile within the last 12 months; **AND**
  - d. Cardiac update if history of cardiac disease within two years ( $\geq 50$  years of age); **AND**
  - e. Psychosocial evaluation or update within the last 12 months; **AND**
  - f. Per initial and updated history and physical, any other clinically indicated tests and/or scans as determined by transplant center physician or Molina Medical Director.
2. If authorized prior requests for transplantation were obtained from another insurer, **ALL** of the following information is required for medical review:
  - a. Authorization letter/documentation from previous insurer; **AND**
  - b. Presence of no absolute contraindication as listed above; **AND**
  - c. History and physical within the last 12 months; **AND**
  - d. Cardiac update if history of cardiac disease within two years ( $\geq 50$  years of age); **AND**
  - e. Psychosocial evaluation or update within the last 12 months; **AND**
  - f. Per initial and updated history and physical, any other clinically indicated tests and/or scans as determined by transplant center physician or Molina Medical Director.

# Molina Clinical Policy

## Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis / Myeloproliferative Neoplasms: Policy No. 324

Last Approval: 10/12/2022

Next Review Due By: October 2023



### Limitations and Exclusions

(NCCN, 2022; NCI, 2022; Majhail et al., 2015; Tefferi & Vardiman, 2008; ECOG, n.d.; <sup>1-5</sup>NMDP, n.d.)

1. Allogeneic (ablative or non-myeloablative) stem cell transplantation when the above criteria are not met.
2. A second or repeat autologous or allogeneic (ablative or non-myeloablative) transplant due to persistent, progressive or early relapsed disease.
3. Autologous stem cell transplantation.
4. Hematopoietic stem cell collection, storage and freezing for a future unplanned transplant is not covered.

**DOCUMENTATION REQUIREMENTS.** Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

### SUMMARY OF MEDICAL EVIDENCE

Peer reviewed publications regarding the efficacy of allogeneic HCT in PMF include retrospective analyses of highly selected populations and small single arm prospective trials. In these groups, estimated survival rates at three to four years range from 40 to 60 percent. The best evidence in support for the use of HCT in this population comes from a retrospective analysis of 438 younger adults (age <65 years) who received HCT (190 patients) or conventional therapies (248 patients), which noted a significant difference in the relative risk (RR) of death after allogeneic HCT versus pre-JAK2 inhibitor conventional therapies according to DIPSS score. Among patients at low risk per the Dynamic International Prognostic Scoring System (DIPSS) model, the relative risk of death after allogeneic SCT vs those treated with nontransplant modalities was 5.6 (95% CI, 1.7-19; P = .0051); for intermediate-1 risk it was 1.6 (95% CI, 0.79-3.2; P = .19), for intermediate-2 risk, 0.55 (95% CI, 0.36-0.83; P = .005), and for high risk, 0.37 (95% CI, 0.21-0.66; P = .0007). Thus, patients with intermediate-2 or high-risk PMF clearly benefit from allogeneic SCT. Patients at low risk should receive nontransplant therapy, whereas individual counseling is indicated for patients at intermediate-1 risk. (Kröger et al., 2015; Robin et al., 2011; Kröger et al., 2009).

Results from a retrospective report using registry data on HCT results in 147 patients with either primary or secondary myelofibrosis showed that four-year OS, PFS and NRM survival were 39%, 32% and 39%. In summary, the published, peer-reviewed scientific literature supports the safety and effectiveness of allogeneic HSCT for the treatment of PMF-MPS in selected individuals. However, improved outcomes have not been demonstrated for autologous HSCT compared with conventional chemotherapy in individuals with PMF-MPS therefore the role of autologous HSCT for this indication has not been established. (Robin et al., 2011).

### National and Specialty Organizations

The **American Society for Blood and Marrow Transplantation (ASBMT)** published *Practice Guidelines: Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation*. Multiple stakeholders were included in the development of the guidelines, including transplant experts and advocates to provide guidance on routine indications for HCT. Recommendations for indications of HCT were categorized by various levels of standard of care as well as those that lack necessary evidence for efficacy. (Majhail et al., 2015).

The **National Comprehensive Cancer Network (NCCN)** (2022) guidelines for the treatment of myeloproliferative neoplasms (MPN) indicate that allo-HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and availability of caregiver. These guidelines include recommendations for allo-HCT and classify the following by Prognostic Category:

- *Low risk or asymptomatic patients* should be observed. Ruxolitinib or interferons should be used for if symptomatic patients.
- *Intermediate Risk (INT-1)*: Evaluation for allo-HCT is recommended for patients with low platelet counts or complex cytogenetics.

**Molina Clinical Policy**  
**Hematopoietic Stem Cell Transplantation for Primary**  
**Myelofibrosis / Myeloproliferative Neoplasms: Policy No. 324**



Last Approval: 10/12/2022

Next Review Due By: October 2023

- *Intermediate Risk (INT-2) and High Risk:* Evaluation for allo-HCT is recommended for all patients who are candidates for transplant. Consider allo-HCT immediately or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant.

The **National Marrow Donor Program (NMDP)** has published the following guidance: *Disease-Specific HCT Indications and Outcomes Data; Engraftment; HLA Matching; Patient Eligibility for HCT; Transplant Consultation Timing; and Treatment Before Transplant.* (1-6 NMDP, n.d.).

The **European Leukemia Net (ELN) and European Blood and Marrow Transplantation Group (EBMT)** have developed consensus recommendations for HCT in PMF [11]. They suggest HCT for patients <70 years of age with intermediate-2- or high-risk DIPSS Plus scores and patients <65 years of age with intermediate-1 DIPSS Plus score with refractory, transfusion-dependent anemia, or a percentage of blasts in the peripheral blood >2, or adverse cytogenetics. (Kröger et al., 2015).

**SUPPLEMENTAL INFORMATION**

None.

**CODING & BILLING INFORMATION**

**CPT Codes**

CPT	Description
	<b>Collection Codes</b>
38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
38230	Bone marrow harvesting for transplantation; allogeneic
38232	Bone marrow harvesting for transplantation; autologous
	<b>Cell Processing Services</b>
38207	Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage
38208	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor
38209	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing, per donor
38210	Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion
38211	Transplant preparation of hematopoietic progenitor cells; tumor cell depletion
38212	Transplant preparation of hematopoietic progenitor cells; red blood cell removal
38213	Transplant preparation of hematopoietic progenitor cells; platelet depletion
38214	Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion
38215	Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer
	<b>Cell infusion codes</b>
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
38241	Hematopoietic progenitor cell (HPC); autologous transplantation
38242	Allogeneic lymphocyte infusions
38243	Hematopoietic progenitor cell (HPC); HPC boost

# Molina Clinical Policy

## Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis / Myeloproliferative Neoplasms: Policy No. 324

Last Approval: 10/12/2022

Next Review Due By: October 2023



### HCPCS Codes

HCPCS	Description
S2140	Cord blood harvesting for transplantation, allogeneic
S2142	Cord blood derived stem-cell transplantation, allogeneic
S2150	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including pheresis and cell preparation/storage; marrow ablative therapy; drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition

**CODING DISCLAIMER.** Codes listed in this policy are for reference purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry standard coding practices for all submissions. When improper billing and coding is not followed, Molina has the right to reject/deny the claim and recover claim payment(s). Due to changing industry practices, Molina reserves the right to revise this policy as needed.

### APPROVAL HISTORY

- |                      |   |
|----------------------|---|
| 10/12/2022           | Policy reviewed, no changes to criteria, included section on marijuana use.                           |
| 10/13/2021           | Policy reviewed, no changes to criteria. Added information from the ASBMT, NMDP – updated references. |
| 9/18/2019, 9/16/2020 | Policy reviewed, no changes, updated references.  |
| 12/19/2018           | New policy.   |

### REFERENCES

#### Government Agency

- Centers for Medicare and Medicaid Services (CMS). Medicare coverage database. National coverage determination (NCD) – Stem cell transplantation 110.23. Available from [CMS](#). Effective Date January 27, 2016. Accessed August 30, 2022.

#### Evidence Based Reviews and Publications

- AMR Peer Review. Policy reviewed October 23, 2018 by an Advanced Medical Reviews (AMR) practicing, board-certified physician in the areas of Oncology, Hematology.
- Chao NJ. Selection of an umbilical cord blood graft for hematopoietic cell transplantation. Available from [UpToDate](#). Updated April 7, 2022. Accessed August 30, 2022. Registration and login required.
- DynaMed. Primary myelofibrosis (record no. 114072). Available from [DynaMed](#). Accessed August 30, 2022.
- Holmberg HJ, Sandmaier BM. Determining eligibility for autologous/allogeneic hematopoietic cell transplantation. Available from [UpToDate](#). Updated February 21, 2022. Accessed August 30, 2022.
- Negrin RS. Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation. Available from [UpToDate](#). Updated August 24, 2022. Accessed August 30, 2022. Registration and login required.
- Tefferi A. Management of primary myelofibrosis. Available from [UpToDate](#). Updated June 3, 2022. Registration and login required.

#### National and Specialty Organizations

- Eastern Cooperative Oncology Group (ECOG) Performance Status. Available from [ECOG](#). Accessed August 17, 2022.
- Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI. Indications for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the American Society for Blood and Marrow Transplantation (ASBMT). *Biol Blood Marrow Transplant*. 2015 Nov;21(11):1863-1869. doi: 10.1016/j.bbmt.2015.07.032. Accessed August 30, 2022.
- National Cancer Institute (NCI). Chronic myeloproliferative neoplasms treatment PDQ. Available from [NCI](#). Updated November 4, 2020. Accessed August 30, 2022.
- National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Myeloproliferative neoplasms (ver. 3.2022). Available from [NCCN](#). Updated August 11, 2022. Accessed August 30, 2022. Registration and login required (free).
- <sup>1</sup> National Marrow Donor Program (NMDP). Disease-specific HCT indications and outcomes data. Available from [NMDP](#).
- <sup>2</sup> National Marrow Donor Program (NMDP). Engraftment. Available from [NMDP](#). Accessed August 30, 2022.
- <sup>3</sup> National Marrow Donor Program (NMDP). HLA matching. Available from [NMDP](#). Accessed August 30, 2022.
- <sup>4</sup> National Marrow Donor Program (NMDP). Patient eligibility for HCT. Available from [NMDP](#). Accessed August 30, 2022.
- <sup>5</sup> National Marrow Donor Program (NMDP). Transplant consultation timing. Available from [NMDP](#). Accessed August 30, 2022.
- <sup>6</sup> National Marrow Donor Program (NMDP). Treatment before transplant. Available from [NMDP](#). Accessed August 30, 2022.
- Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. *Leukemia*. 2008 Jan;22(1):14-22. doi: 10.1038/sj.leu.2404955. Accessed August 30, 2022.

# Molina Clinical Policy

## Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis / Myeloproliferative Neoplasms: Policy No. 324

Last Approval: 10/12/2022

Next Review Due By: October 2023



### Peer Reviewed Publications

1. Kröger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. *Blood*. 2015 May 21;125(21):3347-50; quiz 3364. doi: 10.1182/blood-2014-10-608315. Accessed August 30, 2022.
2. Kröger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: A prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood*. 2009 Dec 17;114(26):5264-70. doi: 10.1182/blood-2009-07-234880. Accessed August 30, 2022.
3. Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: A report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). *Br J Haematol*. 2011 Feb;152(3):331-9. doi: 10.1111/j.1365-2141.2010.08417.x. Accessed August 30, 2022.

### Other Peer Reviewed and Professional Organization Publications (used in the development of this policy)

1. Deeg HJ, Bredeson C, Farnia S, et al. hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: Long-term success in all age groups. *Biol Blood Marrow Transplant*. 2015 Nov;21(11):1883-7. doi: 10.1016/j.bbmt.2015.09.005.
2. Kröger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT/ELN international working group. *Leukemia*. 2015 Nov;29(11):2126-33. doi: 10.1038/leu.2015.233. Accessed August 30, 2022.
3. Lestang E, Peterlin P, Le Bris Y, et al. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era? *Eur J Haematol*. 2017 Jul;99(1):60-69. doi: 10.1111/ejh.12891. Accessed August 30, 2022.
4. National Cancer Institute (NCI). Myelodysplastic syndromes / myeloproliferative neoplasms treatment PDQ. Available from [NCI](#). Updated March 4, 2022. Accessed August 30, 2022.
5. Sliwa T, Beham-Schmid C, Burgstaller S, et al. Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: An expert statement. *Wien Klin Wochenschr*. 2017 May;129(9-10):293-302. doi: 10.1007/s00508-016-1120-8. Accessed August 30, 2022.
6. Soyer N, Celik F, Tombuloglu M, et al. Role of allogeneic stem cell transplant in the treatment of primary myelofibrosis. *Exp Clin Transplant*. 2019 Feb;17(1):93-96. doi: 10.6002/ect.2016.0007. Accessed August 30, 2022.

## APPENDIX

**Reserved for State specific information.** Information includes, but is not limited to, State contract language, Medicaid criteria and other mandated criteria.